← Back to Search

Persons of all ages for Meningococcal Disease

N/A
Waitlist Available
Research Sponsored by Canadian Paediatric Society
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Inclusion Criteria:Neisseria meningitidis isolated or detected by PCR from a normally sterile body site or fluid, such as blood, CSF, joint fluid, pleural, peritoneal, pericardial fluid or tissue biopsy -
Timeline
Screening 3 weeks
Treatment Varies
Follow Up end of 2021
Awards & highlights

Study Summary

Active metropolitan area surveillance for hospital admissions related to invasive infection with Neisseria meningitidis will be conducted at the 12 centers in the IMPACT network in collaboration with Public Health officials, local infection specialists and infection control practitioners during the interval from January 1, 2016 to December 31, 2022.

Eligible Conditions
  • Meningococcal Disease

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~end of 2021
This trial's timeline: 3 weeks for screening, Varies for treatment, and end of 2021 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Laboratory confirmed invasive meningococcal cases.

Trial Design

1Treatment groups
Experimental Treatment
Group I: Persons of all agesExperimental Treatment1 Intervention
Persons of all ages admitted between January 1, 2016 and December 31, 2022 with a positive result of Neisseria meningitidis isolated or detected by PCR from a normal sterile site, such as blood, CSF, joint fluid, pleural, peritoneal, pericardial fluid or tissue biopsy

Find a Location

Who is running the clinical trial?

Canadian Paediatric SocietyLead Sponsor
3 Previous Clinical Trials
3,150 Total Patients Enrolled
PfizerIndustry Sponsor
4,595 Previous Clinical Trials
12,868,370 Total Patients Enrolled
GlaxoSmithKlineIndustry Sponsor
4,772 Previous Clinical Trials
8,106,503 Total Patients Enrolled
11 Trials studying Meningococcal Disease
7,724 Patients Enrolled for Meningococcal Disease
~42 spots leftby Jun 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top